Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Management of elderly patients with advanced non-small cell lung cancer: a single-center experience.

Früh M, Besrour H, Gillessen S, Joerger M, Hitz F, Savidan A, Cerny T, Ess S.

Chemotherapy. 2013;59(1):42-50. doi: 10.1159/000350498. Epub 2013 Jul 2.


Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):60-5. doi: 10.1200/JCO.2007.13.1144.


Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).

Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL.

Lung Cancer. 2006 Aug;53(2):171-6. Epub 2006 Jun 6.


A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.

Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH, Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, Nam SH, Kim BS.

Lung Cancer. 2010 May;68(2):248-52. doi: 10.1016/j.lungcan.2009.06.026. Epub 2009 Aug 3.


Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.

Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, Kiyofuji C, Imamura F, Mori T, Matsumoto M.

Jpn J Clin Oncol. 2005 Apr;35(4):188-94. Review.


Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.

Luo J, Leaw SJ, Xu Y, Zheng D.

Med Oncol. 2011 Dec;28(4):1418-24. doi: 10.1007/s12032-010-9575-3. Epub 2010 Jul 27.


A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.

Ansari RH, Socinski MA, Edelman MJ, Belani CP, Gonin R, Catalano RB, Marinucci DM, Comis RL, Obasaju CK, Chen R, Monberg MJ, Treat J; Alpha Oncology Research Network.

Crit Rev Oncol Hematol. 2011 May;78(2):162-71. doi: 10.1016/j.critrevonc.2010.03.003. Epub 2010 Apr 21.


Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G.

Ann Oncol. 2002 Oct;13(10):1539-49.


Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.

Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.

Cancer. 2002 Sep 15;95(6):1265-73.


Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D.

Cancer. 2013 Jun 1;119(11):2048-60. doi: 10.1002/cncr.28022. Epub 2013 Apr 5.


Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.

Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.

Cancer. 2001 Dec 1;92(11):2902-10.


Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.

Baek JH, Kim H, Ahn JJ, Jegal Y, Seo KW, Ra SW, Park CR, Jung JP, Kim JW, Lee YJ, Cha HJ, Kwon WJ, Noh YJ, Oh S, Park JH, Min YJ.

Lung Cancer. 2012 Jun;76(3):368-72. doi: 10.1016/j.lungcan.2011.11.021. Epub 2011 Dec 20.


Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR.

J Clin Oncol. 2008 Nov 1;26(31):5043-51. doi: 10.1200/JCO.2008.16.4855. Epub 2008 Sep 22.


Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.

Chen LK, Liang Y, Yang QY, Xu F, Zhou NN, Xu GC, Liu GZ, Wei WD.

Asian Pac J Cancer Prev. 2012;13(5):1863-7.


Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk